Page last updated: 2024-11-12
thymic humoral factor gamma 2
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
thymic humoral factor gamma 2: synthetic octapeptide thymic hormone which repairs immunodeficiency of mice cured of plasmacytoma by melphalan [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9897695 |
CHEMBL ID | 2106038 |
SCHEMBL ID | 1230532 |
MeSH ID | M0177811 |
Synonyms (22)
Synonym |
---|
thymoctonan |
thymoctonan [inn] |
thymic humoral factor gamma 2 |
l-leucine, n-(n-(n2-(1-(n-(n-(n-l-leucyl-l-alpha-glutamyl)-l-alpha-aspartyl)glycyl)-l-prolyl)-l-lysyl)-l-phenylalanyl)- |
leucyl-glutamyl-aspartyl-glycyl-proly-lysyl-phenylalanyl-leucine |
n-(n-(n(sup 2)-(1-(n-(n-(n-l-leucyl-l-alpha-glutamyl)-l-alpha-aspartyl)glycyl)-l-prolyl)-l-lysyl)-l-phenylalanyl)-l-leucine |
leu-glu-asp-gly-pro-lys-phe-leu |
unii-5027686086 |
107489-37-2 |
(-)-thymoctonan |
CHEMBL2106038 |
thymic humoral factor-gamma 2 |
thf-gamma 2 |
SCHEMBL1230532 |
(s)-5-(((s)-1-((2-((s)-2-(((s)-6-amino-1-(((s)-1-(((s)-1-carboxy-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxohexan-2-yl)carbamoyl)pyrrolidin-1-yl)-2-oxoethyl)amino)-3-carboxy-1-oxopropan-2-yl)amino)-4-((s)-2-amino-4-methylpentanamido)-5-oxo |
(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[2-[[2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-hydroxy-4-oxobutanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl] |
h-leu-glu-asp-gly-pro-lys-phe-leu-oh |
Q27231280 |
(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid |
HY-125301 |
CS-0090285 |
AKOS040754201 |
Research Excerpts
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"We reported previously that treatment of mice bearing MOPC-315 plasmacytoma with the drugs L-PAM (phenylalanine mustard) or 5-FU (5-fluorouracil), in combination with low doses of THF-gamma 2, was more effective in increasing their survival time than treatment with the drug alone." | ( Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug. Ben-Efraim, S; Burstein, Y; Harshemesh, H; Ophir, R; Pecht, M; Trainin, N, 1991) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (31)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (3.23) | 18.7374 |
1990's | 23 (74.19) | 18.2507 |
2000's | 5 (16.13) | 29.6817 |
2010's | 1 (3.23) | 24.3611 |
2020's | 1 (3.23) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.40) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (8.82%) | 5.53% |
Reviews | 4 (11.76%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 27 (79.41%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |